Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

What this Trial Is About

Researchers are evaluating a non-invasive multi-component liquid biopsy test for patients with urothelial carcinoma, including bladder cancer and upper tract urothelial carcinoma. This observational study aims to assess how well this blood and urine-based test can help diagnose the cancer, monitor treatment response, and predict cancer recurrence. The study is sponsored by Tianjin Medical University Second Hospital and focuses on improving auxiliary diagnosis and monitoring using several tumor-derived markers. The liquid biopsy test combines multiple components such as circulating tumor DNA ctDNA and cell-free DNA from blood plasma and urine, exosomal RNAs, and selected tumor-associated proteins from urine. Samples are collected at key clinical times before diagnosis or at baseline, during treatment, and in the post-treatment surveillance period. This allows researchers to track changes in tumor markers throughout the disease course. Participants will provide paired blood and urine samples for this longitudinal assessment. Researchers will measure diagnostic concordance at baseline and assess dynamic changes during treatment and follow-up visits scheduled at intervals such as 4 to 8 weeks during treatment, and then at 3, 6, 12 months, and yearly up to 24 to 36 months or until disease progression or recurrence. The study involves careful monitoring and sample collection over several years to understand the tests utility in clinical practice.

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma